Peptide Immunogenicity

Immunogenicity — the capacity to provoke an immune response — is one of the most significant challenges in therapeutic peptide development. When the immune system recognizes a peptide drug as foreign, it can generate anti-drug antibodies (ADA) that neutralize the peptide, accelerate its clearance, or trigger adverse reactions ranging from injection site inflammation to life-threatening hypersensitivity. Understanding why immunogenicity occurs and how it is managed is essential for interpreting the clinical behavior of peptide therapeutics.

Why peptides provoke immune responses

The adaptive immune system evolved to detect and respond to foreign proteins and peptides. Therapeutic peptides, even when derived from human sequences, can trigger immune recognition through several mechanisms.

T cell-dependent immunogenicity

The classical adaptive immune response to a peptide therapeutic follows the same pathway as the response to any protein antigen:

1. Antigen uptake: The injected peptide is taken up by antigen-presenting cells (APCs) — dendritic cells and macrophages at the injection site
2. Processing and presentation: APCs proteolytically degrade the peptide and load fragments onto MHC class II molecules on their surface
3. T helper cell activation: CD4+ T helper cells with T cell receptors specific for the peptide-MHC complex become activated
4. B cell help: Activated T helper cells provide signals to B cells that recognize the same peptide, driving their differentiation into antibody-secreting plasma cells
5. Antibody production: Plasma cells secrete anti-drug antibodies (ADA), initially IgM, then class-switched to IgG with affinity maturation over repeated exposures

This T cell-dependent response produces high-affinity, class-switched antibodies that persist and intensify with repeated dosing. It is the most clinically consequential form of immunogenicity.

T cell-independent immunogenicity

Some peptides, particularly those that form aggregates or repetitive structures, can activate B cells directly without T cell help. Aggregated peptides present repeating epitopes that cross-link B cell receptors, bypassing the need for T helper cell assistance. The resulting antibodies are typically IgM, lower affinity, and less persistent than T cell-dependent antibodies, but they can still affect drug pharmacokinetics.

This is one reason why peptide aggregation is a serious pharmaceutical quality concern — aggregated drug product is more immunogenic than properly solubilized monomeric peptide.

Risk factors for immunogenicity

Sequence factors

• Non-human sequences: Peptides derived from non-human species (xenogeneic sequences) are inherently more immunogenic than human-identical sequences
• Sequence modifications: Chemical modifications like non-natural amino acid substitutions, D-amino acids, or backbone alterations can create neoepitopes that the immune system recognizes as foreign
• Length: Longer peptides (roughly > 8-10 amino acids) are more likely to contain T cell epitopes that can be presented on MHC class II. Short peptides (< 8 amino acids) are generally less immunogenic because they are poor substrates for MHC presentation

Formulation factors

• Aggregation: Aggregated peptides are significantly more immunogenic than monomeric peptides. Aggregation creates multivalent antigen displays that efficiently cross-link B cell receptors
• Impurities: Host cell proteins, endotoxin, and oxidized or deamidated peptide variants can act as adjuvants, enhancing immune responses to the therapeutic peptide
• Container leachables: Silicone oil droplets, tungsten residues, and other leachables from syringes and vials can adsorb peptide and create immunogenic complexes

Patient and administration factors

• Route of administration: Subcutaneous injection is generally more immunogenic than intravenous administration because the subcutaneous space is rich in dendritic cells and draining lymph nodes. Intravenous delivery tends to favor tolerance through hepatic and splenic mechanisms
• Dose and frequency: Higher doses can sometimes induce tolerance (high-zone tolerance), while lower doses with intermittent dosing are more likely to provoke immune responses
• Genetic factors: MHC class II haplotype determines which peptide fragments can be presented to T cells. A peptide that is immunogenic in one individual may not be in another due to HLA polymorphisms
• Immune status: Immunosuppressed patients generally develop fewer ADA. Patients with autoimmune disease may have dysregulated tolerance mechanisms that increase immunogenicity risk

Consequences of anti-drug antibodies

Neutralizing antibodies

Neutralizing ADA bind to the active site or receptor-binding region of the therapeutic peptide, directly blocking its pharmacological activity. This manifests clinically as loss of efficacy over time — a patient who initially responds well to treatment experiences progressive therapeutic failure as neutralizing antibody titers rise.

Non-neutralizing antibodies

Non-neutralizing ADA bind to regions of the peptide outside the active site. They do not directly block activity but can alter pharmacokinetics by forming immune complexes that are cleared more rapidly by the reticuloendothelial system. This accelerated clearance reduces drug exposure and may require dose adjustments.

Sustaining antibodies

In some cases, ADA paradoxically extend drug half-life by forming immune complexes that serve as a circulating reservoir, slowly releasing active peptide. This is uncommon but has been observed with certain cytokine therapeutics.

Adverse reactions

ADA can cause injection site reactions (local immune complex deposition), infusion reactions (complement activation), and in rare cases, cross-reactivity with endogenous peptide hormones. Cross-reactive antibodies that neutralize an endogenous hormone are the most dangerous consequence — for example, ADA against an exogenous erythropoietin analog that cross-reacts with native erythropoietin can cause pure red cell aplasia.

Immunogenicity of approved peptide drugs

Immunogenicity rates vary widely among approved peptide therapeutics:

| Peptide drug | ADA incidence | Clinical impact |

|-------------|--------------|-----------------|

| Semaglutide | ~1% | Minimal; rarely affects efficacy |

| Tirzepatide | ~2-5% | Low; neutralizing antibodies rare |

| Liraglutide | ~4-13% | Generally minimal clinical impact |

| Exenatide | ~38-45% | Higher rates; some efficacy reduction |

| Teriparatide | ~3% | No significant clinical impact |

| Insulin (human) | ~1-5% | Rarely clinically significant |

The contrast between exenatide (~39% amino acid identity with human GLP-1) and semaglutide (>90% GLP-1 identity with strategic modifications) illustrates how sequence homology to endogenous peptides reduces immunogenicity.

Strategies to reduce immunogenicity

Sequence engineering

• Humanization: Designing peptide sequences with maximum homology to endogenous human peptides
• T cell epitope removal (deimmunization): Computational identification and mutation of peptide sequences predicted to bind MHC class II with high affinity. Removing T cell epitopes disrupts the T cell-dependent ADA response at its initiation
• Tolerogenic sequences: Incorporating sequences known to engage regulatory T cells (Tregs) that suppress rather than promote immune responses

Chemical modification

• PEGylation: Conjugation with polyethylene glycol (PEG) shields the peptide from immune recognition by creating a hydrated polymer shell that physically blocks antibody and MHC binding. PEGylation also reduces aggregation
• Lipidation: Fatty acid conjugation (as in semaglutide and liraglutide) promotes albumin binding, which both extends half-life and partially shields the peptide from APC uptake
• Glycosylation: Addition of glycan chains mimics the post-translational modifications that help the immune system recognize self-proteins as non-threatening

Formulation strategies

• Minimizing aggregation: Optimizing pH, buffer composition, ionic strength, and surfactant concentration to prevent peptide aggregation during storage
• High purity manufacturing: Reducing process-related impurities that can serve as adjuvants
• Appropriate container closure: Selecting materials that minimize leachable-mediated aggregation

Dosing strategies

• Dose escalation: Gradually increasing dose at treatment initiation may favor immune tolerance over sensitization
• Continuous versus intermittent dosing: Maintaining continuous drug exposure can promote high-zone tolerance, while intermittent dosing with drug-free intervals allows the immune system to "reset" and mount a stronger response upon re-exposure

Immunogenicity assessment in drug development

Regulatory agencies (FDA, EMA) require a tiered immunogenicity testing strategy for all therapeutic peptides:

1. Screening assay: Detects the presence of ADA (typically by bridging ELISA or electrochemiluminescence)
2. Confirmatory assay: Confirms that positive screening results are truly drug-specific (competitive inhibition with excess drug)
3. Neutralizing antibody assay: Determines whether confirmed ADA have neutralizing activity (cell-based bioassay or competitive ligand-binding)
4. Clinical correlation: Assessment of whether ADA status correlates with altered pharmacokinetics, reduced efficacy, or adverse events

Bottom line

Immunogenicity is an inherent risk of therapeutic peptide administration. The immune system can generate anti-drug antibodies that neutralize drug activity, accelerate clearance, or cause adverse reactions. Risk is determined by the peptide sequence (non-human sequences are more immunogenic), its physical state (aggregates are potent immunogens), the route of administration (subcutaneous is more immunogenic than intravenous), and the patient's immune genetics. Modern peptide engineering — humanized sequences, lipidation, PEGylation, T cell epitope depletion, and aggregation-resistant formulations — has substantially reduced immunogenicity rates, as demonstrated by the low ADA incidence with semaglutide and tirzepatide compared to earlier peptide drugs.